DexCom

YTD

ALL

Trade DexCom 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About DXCM

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE.

CEO

Jacob S. Leach

CEOJacob S. Leach

Employees

11,100

Employees11,100

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1999

Founded1999

Employees

11,100

Employees11,100

DXCM Key Statistics

Market cap

29.57B

Market cap29.57B

Price-Earnings ratio

33.35

Price-Earnings ratio33.35

Dividend yield

—

Dividend yield—

Average volume

4.70M

Average volume4.70M

High today

$78.01

High today$78.01

Low today

$75.50

Low today$75.50

Open price

$77.86

Open price$77.86

Volume

5.07M

Volume5.07M

52 Week high

$89.98

52 Week high$89.98

52 Week low

$54.11

52 Week low$54.11

Stock Snapshot

With a market cap of 29.57B, DexCom(DXCM) trades at $75.50. The stock has a price-to-earnings ratio of 33.35.

On 2026-07-18, DexCom(DXCM) stock traded between a low of $75.50 and a high of $78.01. Shares are currently priced at $75.50, which is +0.0% above the low and -3.2% below the high.

DexCom(DXCM) shares are trading with a volume of 5.07M, against a daily average of 4.7M.

During the past year, DexCom(DXCM) stock moved between $54.11 at its lowest and $89.98 at its peak.

DXCM News

Simply Wall St 5h

DexCom Back In Focus As Canada Approval Tests Its Valuation

DexCom (DXCM) stock is back in focus after Health Canada authorized the Dexcom G7 15 Day continuous glucose monitoring system, a longer wear CGM that could broa...

TipRanks 2d

DexCom price target raised to $87 from $80 at Truist

Truist raised the firm’s price target on DexCom (DXCM) to $87 from $80 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 res...

Simply Wall St 3d

How Health Canada’s Longer-Wear CGM Approval At DexCom Has Changed Its Investment Story

Earlier this month, DexCom, Inc. reported that Health Canada authorized its Dexcom G7 15 Day Continuous Glucose Monitoring System for adults with diabetes, exte...

Analyst ratings

83%

of 30 ratings

Buy

83.3%

Hold

16.7%

Sell

People also own

Based on the portfolios of people who own DXCM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.